So far, immune cells that have been engineered to kill cancers, known as CAR T-cells, haven’t worked well against solid ...

Two teams of researchers have developed a cell reprogramming technology that converts rogue disease-causing T cells from our ...

In 2015, Bluestone led a small clinical trial to isolate and grow Tregs from diabetes patients and then reinfuse the cells ...

Nobel laureate Shimon Sakaguchi reflects on the role of regulatory T cells in peripheral immune tolerance and how the cells ...

The FDA has granted orphan drug status to the experimental T-cell, or Treg, therapy CK0803, being developed by Cellenkos to ...

When immune cells strike, precision is everything. New research reveals how natural killer and T cells orchestrate the ...

Regeneron has given up on a CAR-T candidate acquired from 2seventy bio last year before it entered the second part of a phase 1/2 lymphoma study. | Regeneron has given up on a CAR-T candidate acquired ...

In 2006 immunologist and 2025 Nobel prize winner Shimon Sakaguchi co-wrote an article in Scientific American that now feels ...

Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic ...

Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...

Pregnancy and breastfeeding induces the accumulation of specialized immune cells that reduce the chances of breast cancer ...

The goal is to build a front-line defense that will allow the toddler with eyes the size of saucers to lead a more normal ...